Neurodegenerative disease Nervous System Diseases Neurodegenerative disease
Conditions
Interventions
Current interventions as of 24/01/2025:
The examination will consist of the following:
Questionnaire - Participants will complete a questionnaire which includes questions on past medical history, inj
Sponsors
The International Concussion and Head Injury Research Foundation (ICHIRF)
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 24/01/2025: 1. Completed the online screening assessment 2. Participated in elite sport or amateur sport on a regular basis 3. Can understand and participate in the testing procedures 4. Are able to provide informed consent for participation 5. Are now retired from active participation in competitive sport Previous inclusion criteria: 1. Completed the online screening assessment 2. Participated in elite sport 3. Can understand and participate in the testing procedures 4. Are able to provide informed consent for participation
Exclusion criteria
Exclusion criteria: 1. For the questionnaire study if they are aged <18 years and ineligible for the phenotyping <50 years 2. Have a history of previous severe traumatic brain injury 3. Are on current psychotropic medication 4. They have a pre-existing medically-diagnosed neurological disorder (e.g. Alzheimer’s dementia, Parkinson’s disease, Multiple Sclerosis, Motor Neuron Disease) 5. The participant is currently enrolled in a disease modifying therapeutic (drug or interventional) trial 6. Presence of any of the following clinical conditions: Substance abuse within the past year; Unstable cardiac, pulmonary, renal, hepatic, endocrine, hematologic, or active malignancy or infectious disease; AIDS or AIDS-related complex; Unstable psychiatric illness defined as psychosis (hallucinations or delusions) or untreated major depression within 90 days of the screening visit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Neurodegenerative disease (e.g. Alzheimer's Disease) will be a clinical diagnosis supported by neuropsychological, radiological, pathological and/or fluid biomarker changes and in line with international diagnostic criteria measured as follows: 1. A questionnaire which includes questions on past medical history, injury history, concussion history, playing history, sleep, mood 2. Sports Concussion Assessment Tool 3/5 3. Physical and Neurological examination - The neurological examination will be performed by a consultant neurologist following a standardized exam protocol. Physical examination will include visual acuity and colour vision using Isihara plates, urinalysis and University of Pennsylvania - Brief Smell Identification Test 4. Balance Assessment: each subject will perform a balance test using the SWAY iPhone app 5. Computerized Neurocognitive Screen - Participants will complete the CogState Brief Battery, a validated computerized cognitive assessment, which includes four separate tasks: Processing Speed (simple reaction time), Attention (choice reaction time), Learning (visual recognition memory) and One Back (Working Memory test) 6. Neuropsychological assessment - Neuropsychological tests for the current study will be selected on the basis of a study into neuropsychological function following repeat concussion in active jockeys. The total administration time for the neuropsychological battery will be approximately 60 minutes and will be performed by a consultant clinical neuropsychologist. 7. Anatomical and functional magnetic resonance imaging (MRI) will be acquired for all subjects. MRI studies will be performed using a 3.0 Tesla Siemens scanner using a 32-channel head coil 8. Visual Saccadic testing - Saccadic latencies (reaction times) will be recorded using a portable, microminiaturised head-mounted saccadometer 9. Blood testing - Participants in this study will have blood drawn and labelled at baseline and each assessment time point. Blood will be | — |
Secondary
| Measure | Time frame |
|---|---|
| Age-related cognitive changes in this population will be a clinical diagnosis supported by neuropsychological, radiological, pathological and/or fluid biomarker changes and in line with international diagnostic criteria. Predictors will be based on the study measures listed in the primary outcomes. | — |
Countries
England, Ireland, United Kingdom
Outcome results
None listed